Fluidigm Revenues Increase 21 Percent in Q3 as It Files Suit Against NanoString | GenomeWeb

NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market Wednesday that its third-quarter revenues increased 21 percent year over year driven by strong consumables growth.

The firm also said in a separate announcement Wednesday that it has filed litigation against NanoString Technologies alleging deceptive marketing practices in an advertising campaign for its nCounter gene expression assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.